Ignite Creation Date:
2024-05-05 @ 6:41 PM
Last Modification Date:
2024-10-26 @ 9:36 AM
Study NCT ID:
NCT00525447
Status:
COMPLETED
Last Update Posted:
2014-10-09
First Post:
2007-08-31
Brief Title:
Study of SGN-40 Lenalidomide and Dexamethasone in Patients With Multiple Myeloma
Sponsor:
Seagen Inc
Organization:
Seagen Inc
Study Overview
Official Title:
A Phase I Study of SGN-40 Anti-huCD40 mAb Lenalidomide Revlimid cc 5013 and Dexamethasone in Patients With Multiple Myeloma MM
Status:
COMPLETED
Status Verified Date:
2014-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase I open-label multi-dose trial to define the MTD and tolerability of a regimen including lenalidomide dexamethasone and intravenous SGN-40 in patients with relapsed multiple myeloma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None